Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

One of the largest pharmaceutical companies in North Carolina is discontinuing a treatment produced in the state.

Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

Mylan, which has an established presence in the central nervous system therapy segment, is expected to leverage its network ...

The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.

There are plenty of great investment alternatives in the healthcare sector. You won't need a boatload of money to get started, either. Here are two no-brainer healthcare stocks to buy with $500 right ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Pfizer has announced that it has entered into a marketing and supply agreement with Mylan Pharmaceuticals for the marketing and sale of two of its brands, Ativan and Pacitane.

Donald Trump has instructed pharmaceutical companies to relocate their production to the United States, warning they could ...

Pfizer (NYSE: PFE) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent ...

US aid freeze affects HIV and malaria supply chains, FDA postpones rare disease events, and a leap in Texas measles cases. Meanwhile, Mirum Pharma's drug gets FDA approval, Eli Lilly invests in a ...